Nancy Abdel-Wahab, MD
Psychiatry · Brooklyn, NYNPI 1639207350
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $196,972 of the $253,169 with a category attached, or 77.8%. 20 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 51.0% of the total. 2025 is the largest year on record at $65,462, 7.0 times the $9,353 reported in 2019. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,039 payments — averaging $243.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$129K
- Alkermes, Inc.$47K
- AbbVie$39K
- E.r. Squibb & Sons, L.L.C.$32K
- Otsuka America Pharmaceutical, Inc.$917
- Johnson & Johnson$911
- plus $4K from 14 others
What the payments were for
- Consulting fees$17,9157%
- Speaking & faculty fees$196,97278%
- Travel & lodging$13,9336%
- Food & beverage$23,7519%
- Education$5980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 322 | $129,228 |
| Alkermes, Inc. | 161 | $46,909 |
| AbbVie(2 entities) | 164 | $39,416 |
| E.r. Squibb & Sons, L.L.C. | 92 | $31,635 |
| Otsuka America Pharmaceutical, Inc. | 47 | $917 |
| Johnson & Johnson | 42 | $911 |
| Lundbeck LLC | 57 | $886 |
| Sunovion Pharmaceuticals Inc. | 39 | $675 |
| Neurocrine Biosciences, Inc. | 34 | $661 |
| Axsome Therapeutics, Inc. | 24 | $551 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $264 |
| Vanda Pharmaceuticals Inc. | 12 | $264 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $252 |
| Immedica Pharma US, Inc. | 1 | $225 |
| Indivior Inc. | 8 | $146 |
| Avanir Pharmaceuticals, Inc. | 4 | $87 |
| Noven Therapeutics, LLC | 4 | $66 |
| Luye Pharma (USA) Ltd. | 1 | $34 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$253,169 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 29 | $215,820 |
| RexultiBrexpiprazole | 121 | $176,591 |
| Abilify MaintenaAripiprazole | 59 | $145,319 |
| VraylarCariprazine Hcl | 87 | $133,150 |
| Invega TrinzaPaliperidone Palmitate | 12 | $112,050 |
| Invega SustennaPaliperidone Palmitate | 22 | $66,327 |
| OzempicSemaglutide | 52 | $48,489 |
| AristadaAripiprazole Lauroxil | 13 | $44,653 |
| LybalviOlanzapine/Samidorphan Malate | 27 | $41,390 |
| BelsomraSuvorexant | 93 | $38,797 |
| MounjaroTirzepatide | 24 | $27,794 |
| CaplytaLumateperone Tosylate | 17 | $27,083 |
| TrintellixVortioxetine Hydrobromide | 34 | $22,545 |
| JardianceEmpagliflozin | 14 | $13,522 |
| Lurasidone Hcl | 37 | $8,891 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $917 | $321,910180 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $129,228 | $215,82029 claims |
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $911 | $178,37634 claims |
| AbbVieVraylar | $39,416 | $133,15087 claims |
| Alkermes, Inc.Aristada, Lybalvi | $46,909 | $86,04240 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $264 | $27,08317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $252 | $22,54534 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $24 | $6,03513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Brooklyn
- Mark OwensBrooklyn$286K
- Stephan CarlsonBrooklyn$184K
- Louis BelzieBrooklyn$161K
- Nikhil PalekarBrooklyn$115K
- Alexander PinkusovichBrooklyn$95K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.